产品名称 | NebuSelect™ Recombinant Mouse LYPD3, His-tag |
---|---|
目录号 | NBL-242333 |
别名 | LYPD3; MIG-C4; LYPD3; C4.4A; LY6/PLAUR domain containing 3 |
外观 | see COA |
分子量 | Leu33-His287 |
CAS | N/A |
溶解度 | Water Soluble |
存储条件 | Short term 4℃; Long term -20℃. |
保存时间 | 2 years |
备注1 | Q91YK8 |
备注2 |
目录号 | 规格 | 价格 | 库存状态 | |
NBL-242333-100ug | 100ug | Inquire | Inquire | |
NBL-242333-1mg | 1mg | Inquire | Inquire | |
NBL-242333-Customized Size | N/A | Inquire | Inquire |
Product Name:
NebuSelect™ Recombinant Mouse LYPD3, His-tag
Catalog#:
NBL-242333
Description:
NebuSelect™ Recombinant Mouse LYPD3, His-tag(Cat#NBL-242333) is expressed in HEK293 with His tag at the C-Terminus.It contains Leu33-His287.
Species:
Mouse
Expression System:
HEK293
Molecular Weight:
The protein has a predicted MW of 27.6 kDa. Due to glycosylation, the protein migrates to 70-80 kDa based on Bis-Tris PAGE result.
Target Name:
LYPD3; MIG-C4; LYPD3; C4.4A; LY6/PLAUR domain containing 3
Target Information:
Aberrant expression of LYPD3 plays an oncogenic role in several types of cancer.LYPD3 was able to be regulated by the methylation in LYPD3 promoter region, which was positively associated with the overall survival. Furthermore, we explored the related pathways through which LYPD3 affects the pathogenesis and prognosis of LUAD by gene set enrichment analysis, and found that LYPD3 might affect the clinical manifestations of LUAD by regulating the P53 signaling pathway.
Amino Acid Sequence:
Leu33-His287
Purity:
>95%
Formulation:
see COA
Endotoxin:
<1EU/ug(LAL Method)
Storage:
4°C for short term.
-20°C for long term.
To get more information, please contact us freely.